List of exhibitors

5.9 S.r.l. is an Italian leading company of weighing systems for medical applications. Monitoring the patient’s weight during invasive medical treatments, such as dialysis, allows the medical staff to verify the patient’s health conditions just in a glance.
Our product range includes bed scales, armchair scales and customizable weighing systems in accordance with any customer need.
We developed an integrated weighing system with touch display, able to create a dedicated patient file, complete with the treatment information and the patient medical history.
Moreover, we complete our product range with comfortable therapy armchairs for medical purpose.

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for nearly 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.

ALKALOID AD Skopje is a company that has been operating in the
field of manufacturing drugs, cosmetic and chemical products and
processing botanical raw materials, for almost nine decades.
Nowadays, ALKALOID sells its products in more than 50 countries
worldwide, with over 3.000 employees.
Haemodialysis solutions have been part of the company’s medical
portfolio since 1990, and now, three decades later, we launched state of-the-art manufacturing facilities, fully automated manufacturing,
that allows for fast, accurate, and reliable operation for this type of
product, with an annual production output of nearly 15 million liters.
The special robotic line can fill and package 7.500 litres of ready-to use haemodialysis concentrates per hour.
In 2010, ALKALOID’s solutions for haemodialysis were CE-certified
by DEKRA Certification B.V., a Notified Body from Netherlands, for
compliance with the European Medical Devices Directive.

Innovation, collaboration and a commitment to improve patient care – welcome to Allmed.
We’re here to make a real difference. To clinicians, to patients, and to the delivery of the very best renal care therapies, whenever and wherever they’re needed.
Every day, we harness our skills in development and manufacturing – and our commitment to quality assurance – to distribute a vast range of high quality dialysis products around the world.
And we can put these skills to work to create bespoke solutions for you, too. Talk to us. We can develop, brand and manufacture a range of extracorporeal applications.
That’s because research and development is at the heart of what we do.
We operate three international R&D centres, each focused on a specific area of excellence. Together, these centres enable us to deliver fast market responses, proactively and efficiently.
We were founded to continuously improve the quality of life of patients with kidney disease – and we do this by offering innovative products and treatment methods of the highest quality with unsurpassed flexibility.

With flexibility, ingenuity and collaboration, we’re making a real difference to people’s lives, across the globe.

Alnylam is leading the translation of RNA interference into a whole class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, infectious and central nervous system and ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for treating a wide range of severe, debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam is headquartered in Cambridge, MA.
Alnylam has funded the scientific medical educational part of the meeting only.

We have developed new medical devices and therapeutic technologies We have achieved these through a high-level synergy of filtration and separation technologies using membranes, filters and adsorbents, together with wide-ranging knowledge and technological expertise in science, mechanical engineering and medical fields. Our filtration and separation technologies for blood and body fluids hold great promise as core technologies for integrative innovation.

Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into VALUE for patients.

For more information, please visit our website at https://www.astellas.com/en.

AstraZeneca in CVRM
Cardiovascular, Renal and Metabolism (CVRM), part of BioPharmaceuticals, forms one of AstraZeneca’s main disease areas and is a key growth driver for the Company. By following the science to understand more clearly the underlying links between the heart, kidneys, liver and pancreas, AstraZeneca is investing in a portfolio of medicines for organ protection by slowing or stopping disease progression, and ultimately paving the way towards regenerative therapies. The Company’s ambition is to improve and save the lives of millions of people, by better understanding the interconnections between CVRM diseases and targeting the mechanisms that drive them, so we can detect, diagnose and treat people earlier and more effectively.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide.

Please visit astrazeneca.com and follow the Company on social media @AstraZeneca

B. Braun is one of the world’s leading medical technology companies. With 63,000 employees, the family-owned company is a true partner, developing smart solutions and setting standards to drive advancements in health care. In 2023, the B. Braun Group generated sales of € 8.8 billion.

Founded in 2003, Bain Medical Equipment (Guangzhou) Co., Ltd. is a national high-tech enterprise with a registered capital of 53 million US dollars and a total investment of over RMB 3 Billion. Headquartered in Huangpu,Guangzhou, the company has more than 5,000 employees worldwide.

With the adherence to the quality policy “quality is life, quality creates glory” and the full knowledge that technological innovation is productivity, Bain Medical is devoted to independent technology innovation and quality optimization, developing advanced fully automatic production lines to improve production efficiency and quality.

Bain Medical manufactures a complete portfolio of hemodialysis devices with high performance, which include HD machine, hemodialyzer, blood tubing sets, AVF needle, disposable care kit and etc., which can suit different markets and patients’ needs.

The company adheres to scientific management system and is ISO 13485 certified. It has passed NMPA certification and EU CE certification for almost all products, and some products are even US 510K cleared.

Bain Medical ‘s production and marketing network covers more than 100 countries and regions. With the Greater Bay Area as the center, it has six R & D and production sites worldwide. Its branches and warehousing and logistics centers have been set up in Turkey, Malaysia, Pakistan, India, Thailand, Brazil, Mexico, Colombia and etc. Being professional manufacturer of blood purification products, it aims to provide professional and convenient services for global customers and serve the patients with high quality product.

Bayer is a life science company and a global leader in healthcare and nutrition. Our innovative products support efforts to overcome the major challenges presented by a growing and aging global population.

Bayer is a life science company with three divisions:
– Crop Science / Innovative cropping systems, seed and trait technologies, sustainable crop protection, new fertilizers, carbon farming, data and digital solutions.
– Pharmaceuticals / Prescription products for cardiology, women’s healthcare, oncology, hematology, ophthalmology, radiology and other areas.
– Consumer Health / Non-prescription medicine in the categories of nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health.

For more information, go to www.bayer.com

Bio Preventive Medicine Corp. is a leading company in novel renal biomarker
area. As an innovative and clinical staged biotech company, BPM focuses on
developing novel biomarker-based diagnostics for chronic diseases and
oncology. Our mission is poised to develop novel and high valued diagnostic
product, including IVD and lab service. One of our highlight products,
DNlite-IVD103, is an ELISA based non-invasive urinary test for prognosis
of kidney function for diabetic kidney disease, DKD and kidney transplantation recipients. Unlike the current standard
test (known as eGFR and UACR) can only detect the disease once it’s already
present, DNlite-IVD103 predicts kidney function loss years in advance.

Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.

Boehringer Ingelheim and Eli Lilly and Company
The Boehringer Ingelheim and Lilly Alliance leverages the strengths of two of the world’s leading pharmaceutical companies. By joining forces, the companies demonstrate their commitment, not only to the care of people with type 2 diabetes, but also to address areas of unmet medical need like heart failure and chronic kidney disease.

About Boehringer Ingelheim
Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units, Human Pharma and Animal Health. Learn more at www.boehringer-ingelheim.com.

About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer’s disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.

Boehringer Ingelheim and Eli Lilly and Company
The Boehringer Ingelheim and Lilly Alliance leverages the strengths of two of the world’s leading pharmaceutical companies. By joining forces, the companies demonstrate their commitment, not only to the care of people with type 2 diabetes, but also to address areas of unmet medical need like heart failure and chronic kidney disease.

About Boehringer Ingelheim
Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units, Human Pharma and Animal Health. Learn more at www.boehringer-ingelheim.com.

About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer’s disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram and LinkedIn.

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Learn more at www.boehringer-ingelheim.com.

Chiesi Global Rare Diseases is a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases. As a family business, Chiesi Group strives to create a world where it is common to have a therapy for all diseases and acts as a force for good, for society and the planet. The goal of the Global Rare Diseases unit is to ensure equal access so as many people as possible can experience their most fulfilling life. The unit collaborates with the rare disease community around the globe to bring voice to underserved people in the health care system. For more information visit www.chiesirarediseases.com.

CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency and nephrology. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier lives. Headquartered in St. Gallen, Switzerland, CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care). The parent company, CSL (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs 32,000 people and delivers its lifesaving therapies to people in more than 100 countries
For more information about CSL Vifor, visit CSLVifor.com.

Our engineering company designs, develops and manufactures biomedical devices mainly based on optoelectronics technologies, focused on the following areas:
-Cardiopulmonary support
-ECLS (ExtraCorporeal Life Supports)
-Hemodialysis
-Organ preservation
Projects are managed from design phase, through engineering, technical support for validation, certification, production, and after-sales service.
Our optical sensors measure blood parameters essential for life such as Oxygen Saturation, Hematocrit, Hemoglobin, Oxygen Partial Pressure and Blood temperature.

Dialife, headquartered in Switzerland, is a leading global provider of high-quality renal care products, equipment, and services. Our mission is to support healthcare providers in delivering safe, reliable, and effective hemodialysis treatments. We offer an extensive portfolio of advanced dialysis solutions, including state-of-the-art dialysis machines, high-performance dialyzers, tubing sets, fistula needles, bicarbonate cartridges, concentrate solutions, disinfectants, endotoxin filters, on/off kits, and more.

Beyond our comprehensive product line, we empower clinics and hospitals with end-to-end solutions for setting up fully equipped hemodialysis centers. Additionally, Dialife facilitates technology transfers, enabling local production of dialysis products to meet regional needs. We are committed to advancing renal care globally by providing exceptional support and innovative solutions tailored to the needs of each healthcare provider and patient community.

Dimerix is a clinical-stage biopharmaceutical company, with a portfolio of drug candidates for inflammatory diseases, including kidney and respiratory disease

The ACTION3 study by Dimerix is a Phase 3 study to determine whether the investigational medication DMX-200 is effective and safe in treating a rare kidney condition called Focal Segmental Glomerulosclerosis (FSGS). Dimerix is currently enrolling participants globally for the ACTION3 study.

Since 40 years, DWA has specialized in innovative solutions for the supply of high purity water to dialysis centers – worldwide. DWA develops systems for the production of ultrapure permeate and its distribution right to the dialysis machine. Our expertise in water treatment covers all aspects from the pre-treatment stages, through reverse osmosis, ultrafiltration and heat-disinfection systems, right up to the supply connection through to the dialysis machine. In addition, DWA offers systems for the distribution of acid and bicarbonate concentrates. Since its inception, DWA has been setting standards in dialysis water treatment and is the only company producing ultra-clean permeate by the combination of reverse osmosis and central ultrafiltration, including integrated simultaneous heat-disinfection of the ring mains to the dialysis machines. DWA is your global partner for the design, planning, installation, extension or conversion of dialysis centers and offers project management, installation and commissioning as well as service and maintenance from a single dedicated source.

EchoNous is pioneering a new category in POCUS – the only one to offer top-tier image quality + AI fueled interpretations, and cutting-edge innovations at the point-of-care. With cart benchmarked quality and advanced feature sets such as PW, CW, Color Doppler, and TDI, previously only seen on larger, more expensive systems, Kosmos ultraportable ultrasound is giving physicians a higher level of confidence in their bedside diagnosis.

We have been producing single use sets for more than 40 years. Focused on the Haemodialysis market, producing bloodlines and accessories, in the last years we have implemented our range adding oncology, infusion and transfusion sets.
Where the major players offer just some standard models, we have more than 300 different models, dedicated to specific customer’s requests.
Our company structure, always evolving, allows us to promptly react to the increasing requirements of the market. Our customers have confidence in us as a reliable partner with a track record of long-lasting cooperation.
On time delivery and service are our standard.

Lilly unites caring with discovery to create medicines that make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer’s disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/newsroom or follow us on Facebook, Instagram, Twitter and LinkedIn.

Emerald Clinical is a leading global clinical research organization founded in Asia-Pacific driven by scientific expertise and operational excellence. With over 20 years of experience and more than 500 people managing 40 geographical locations throughout the Asia-Pacific region, USA, and Europe, Emerald Clinical provides a full range of clinical trial services to biopharmaceutical, medical device, and diagnostic customers for all trial phases, registration, and post-marketing trials.

Emodial is an Italian company that develops advanced solutions for the vascular access management in dialysis: the Silver line of pads, plasters and pockets for CVCs, peritoneal catheters and PICCs releasing silver ions with antibacterial and anti-inflammatory action, also available in procedural kits for start/end treatment and, upon completion of advanced dressings, the innovative waterproof pockets for catheter, for bath and shower.

“Etropal” JSC is a leading company in the field of production of disposable medical devices since 1976.
Patient health is at the center of everything we do – and we follow this principle to meet the ever-increasing demands on dialysis products, especially in the areas of design, working materials and manufacturing. As a medical device manufacturer, we give top priority to safety and reliability. All our medical products are certified according to the European Medical Devices Directive 93/42 / EEC. Production and sales are also part of an audited quality management system. In this way, it has firmly integrated quality assurance processes in all areas of work: from idea to market. In addition,continuous control at the various stages of production ensures consistently high quality of Etropal’s end products. With over forty years of experience in the research and development and manufacturing of medical devices, Etropal offers a wide range of products that meet the individual needs of each patient.

About Eurofins Biomnis
Eurofins Biomnis is a major player in specialised clinical diagnostics in Europe offering a variety of over 2,000 tests enabling physicians to make clear and reliable decisions. Clinical diagnostics is at the heart of therapeutic decisions thanks to screening, diagnosis, treatment response prediction and patient monitoring. Building on its 125 years of expertise, we continue to innovate and use progress in molecular biology to offer tests with high medical added value for accurate and personalised patient management, particularly in nephrogenomics. Learn more at www.eurofins-biomnis.com

About Eurofins Transplant :
Through Pre-Transplant, Post-Transplant & Infectious Disease Management and Post-Transplant Rejection Biomarkers, we harness the power of five companies to meet your needs. We integrate: We harness the power of our network of companies to deliver comprehensive solutions across the transplant spectrum. We Innovate: We never stop moving forward and are always looking for solutions that will solve the complex challenges of tomorrow. We inform: We empower patients and providers to make informed decisions about current treatments and future therapies. Learn more at https://eurofinstransplant.com/ and at Eurofins Transplant ebook.

FARMASOL was founded in 2005 and started its operations with a 2550 m2 production site Kayseri. FARMASOL produced there as its first product hemodialysis solutions and disinfectants. Between 2005 and 2007, production was expanded 2 times: a first time to 4350 m2 and in 2007 with another 1800 m2 of space. Farmasol then began producing arterial venous sets and fistula needles in “Class 10000 clean rooms.” In 2008, Farmasol became the official Turkish distributorship of DWA, also a member of Pollet Medical Group and a leading global company in the field of water treatment for hemodialysis centers. In 2012, Farmasol began producing bicarbonate cartridges and bicarbonate bags. In early 2013, the company built an additional 2,150 m2 plant for its for its dialyzer production. In 2024, Farmasol became part of Pollet Medical Group, a global player active in dialysis, plasma apheresis and sterilization.

Firapy Medical is a specialized company dedicated to the sales and promotion of FIRAPY, a unique and innovative far-infrared therapy device. As the only device in the world with clinical evidence supporting its ability to improve hemodialysis vascular access function, FIRAPY has been recognized in major guidelines, including K/DOQI and ERBP, which recommend far-infrared therapy for maintaining and enhancing fistula function.

With extensive experience in hemodialysis vascular access care, wound care, ischemia management, and PAD/diabetic foot care, we are committed to delivering scientifically backed far-infrared therapy to improve patient outcomes and quality of life.

The Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e. V. is the largest organization for applied research and development services in Europe. The Fraunhofer Institute for Cell Therapy and Immunology IZI researches and develops special problem solutions at the interfaces of medicine, biosciences and engineering. One of its main tasks is contract research for biotechnological, pharmaceutical and medical technology companies, clinics, diagnostic laboratories and research institutes. At our location in Rostock, the Department of Extracorporeal Therapy Systems is dedicated to the development of new diagnostic and treatment procedures in the field of extracorporeal organ replacement systems.
A particular highlight is our ASSESS-MED test laboratory, which acts as a service center for the evaluation of medical devices for blood purification.
The laboratory offers standardized, industry-oriented product testing to support the faster transfer of new technologies to the market. The test portfolio includes comprehensive performance evaluation methods as well as biological safety tests.

Frenova is a global site management organization dedicated to the success of clinical research.

Frenova, a Fresenius Medical Care company, is a global site management organization dedicated to the success of clinical research.

Frenova delivers a network of research sites, a diverse patient population, and the expertise and infrastructure to get your trial up rapidly. We work with partner sites to enroll suitable patients for renal trials and studies of adjacent conditions.
We also offer advanced data analytics and data licensing services, with access to one of nephrology’s largest longitudinal databases in order to unleash the power of Real-World Evidence results for you.

Fresenius Medical Care is the world’s leading provider of products and services for individuals with renal diseases of which around 4.2 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,675 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 299,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers.

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Our R&D focus is on four therapeutic areas: infectious diseases, HIV, immunology/respiratory and oncology. We also have a special interest in nephrology and a commitment to the community impacted by renal disease. We are proud to be joining experts from around the world to discuss our science, create opportunities to connect with peers and deliver compelling content at this years ERA congress.

Please visit us at our booth, attend our industry symposia and spotlight sessions to learn more about GSK in nephrology.

Founded in 1993, BIOLIGHT is an internationally established leading provider in medical devices, medical consumables, and healthcare solutions. Including patient monitoring, emergency responds, hemodialysis renal care, and digital health homecare solutions. Biolight has established 8 researches and manufacturing plants, 12 subsidiaries, and oversea sales branches covering sales and services in Asia, Africa, Europe, North America, and Latin America expanding over 135 countries and counting. BIOLIGHT will continue to maximize the impact of our corporate responsibility programs by leveraging our unique company resource in biomedical engineering and digital health creating a platform to better focusing on generating values for our society.

Top quality is sustainable: Herco develops, designs and manufactures durable water technology for industry and medicine. We have been offering reliable solutions for over 75 years – Made in Germany. We promise you tested quality, comprehensive service and a customer-orientated engineering for a secure future.
Herco develps systems for hemodialysis in accordance with MDR which provide maximum hygiene and operational safty. Our dialysis water treatment is efficient and conserves resources.
In the CSSD, pure and ultrapure water is essential for the hygienic reprocessing of medical devices. Herco offers systems with thermal disinfection that fulfill DIN EN ISO 285 and guarantee maximum hygiene.

ICU Medical is a global leader offering clinically essential products and solutions that connect patients with caregivers through life-enhancing, innovative technology. Our robust portfolio features products for medication delivery, critical care, monitoring, and patient safety that help provide precision, accuracy, and reliability across the continuum of care.

IgANexus is a peer-to-peer scientific education resource developed in collaboration with nephrology and immunology experts, funded by Calliditas Therapeutics AB. The mission of IgANexus is to advance awareness and understanding of pathophysiology and evidence-based care in IgA nephropathy.

Calliditas is dedicated to expanding treatment options and establishing new standards of care for people with rare diseases. By drawing on our expertise in pharmaceutical product development and leveraging our strategic partnerships, we quickly and efficiently identify, develop, and market a pipeline of innovative medicines that can improve the lives of patients. We successfully commercialized our lead candidate in the United States, and in collaboration with our partners, received approvals in Europe and Asia.

Immundiagnostik AG is an internationally active diagnostics company developing and manufacturing innovative immunoassays, LC-MS/MS, HPLC, PCR and other analytical detection methods for medical routine and research.
Immundiagnostik provides novel immunoassays and analytical tools focused on gastroenterology, nutrition, cardiovascular and renal diseases, bone metabolism, clinical immunology, oncology and more.
In addition we offer a wide range of antibodies and antigens, laboratory support services, including proficiency testing and validation assistance. Visit Immundiagnostik to discover more about our products, services, and brands.

InBody introduced the world’s first Body Composition Analyzer, InBody, which utilized Direct Segmental Multi-Frequency Measurements.

In an era where there was no technology to accurately measure body composition, we pioneered a new market by commercializing a professional Body Composition Analyzer that ensures precision and reproducibility in measurements.

While setting the trusted standard for Body Composition Analysis, the InBody Test has become the norm for Body Composition Analysis.

Our aim is to raise public awareness of the importance of body composition, and in doing so change the way people think about health. InBody has established itself as the most practical and reliable Body Composition Analyzer brand in the world.

Infomed, worldwide player on blood purification devices offers complete solutions for chronic and acute renal replacement (homecare and hospital environment) and for plasma therapies. Active since more than 25 years, Infomed continuously innovates to create devices designed to reach your topmost needs. Dimi, our homecare dialysis device, is the partner for a new life at home. Dimi was thought to offer the freedom to provide the optimal treatment conditions fulfilling the patient requirements thanks to various therapies available such as peritoneal dialysis and hemodialysis.
Our products are adapted for adult, child and babies. We work for human well-being thanks to a large range of treatments available on our devices which include the “all in one” philosophy, as Infomed, we focus on you!

Jafron Biomedical was established in 1989, as a global provider of technology, products, and therapy services in the hemoadsorption industry. Jafron products focus on removing toxins in blood for different diseases, covering critical care, nephrology, hepatology, immunological diseases, etc. With more than 20 years of clinical experience, Jafron hemoadsorption treatments have been adopted in over 8000 hospitals in 80 countries, with about 5 million cases of clinical application annually.

Listed on ChiNext in 2016, Jafron is now a leading enterprise in the Chinese blood purification industry. In 2020, as a comprehensive adsorption solution provider, Jafron will keep exploring other novel medical fields to realize the vision of “Health Technology for a Better World”.

Jiangxi Hongda Medical Equipment Group Ltd., established in 1987 is a leading manufacturer of disposable medical devices in China.
Hongda Group has total assests of RMB 25billion and registered capital of RMB 428.88million. Total land area is approximately 600,000m2 including 60,000 square meters of 100,000 class cleaning room, with total staff nearly 6000. Owning the biggest production scale in China, its annual output of disposable medical products reaches 4 billion pieces.

Hongda products are CE,ISO, SFDA approved. The domestic market share is up to 25%. Products have been exported to South America, Europe, Africa and Asia,etc, which is up to more than 80 countries.

Hongda Products cover eight categories: infusion and transfusion sets, syringes, puncture products, anaesthetic products, catheter products, examination and assistance products, hemodialysis products and protective products.

Jiangxi Sanxin Medtec Co., Ltd. (Stock Code: 300453) offers five comprehensive product
solutions: blood purification, vascular intervention, drug delivery, diabetes care, and cardiothoracic surgery. As the first and only Jiangxi-based medical device company listed on the
A-share market, Sanxin is committed to “enhancing patients’ quality of life.” Leveraging scientific innovation, intelligent manufacturing, and digital transformation, Sanxin strategically
develops advanced productive forces. As a leading player in China’s hemodialysis sector,
Sanxin distinguishes itself with outstanding products and exceptional services, driving
high-quality development in the healthcare industry.
As the lead entity of Jiangxi Province’s High-Performance Medical Device Industry Science and Technology Innovation Consortium, Sanxin has actively contributed to the revision
and formulation of over 20 national and industry standards, setting a benchmark for the
high-quality development of Jiangxi’s medical device industry.

JIHUA MEDICAL
Purifying Every Hope

Founded in 2000, after more than 20 years of technology development, JIHUA MEDICAL has evloved into a leading manufacturer of blood purification devices, a supplier of supporting consumables and a service provider of hemodialysis centers in China.

As the first high-tech enterprise in China with independent intellectual property rights in blood purification equipment, Jihua Medical has consistently focused on the research, development, manufacturing, distribution, and service of blood purification devices and consumables, as well as the operation of hemodialysis centers for the past twenty years. It is a comprehensive enterprise integrating production, education, and research, recognized as a key high-tech enterprise under the National Torch Plan.

Joline GmbH & Co. KG is an internationally operating medical technology company that sells a wide range of dialysis catheters, balloon catheters and stents for various indications worldwide. The long-established German company, which has been based in Hechingen for over 20 years, is divided into four successful divisions: Dialysis, Kyphoplasty, Cardiology and Stents & OEM division. All Joline medical devices are developed and manufactured in Germany.

When it comes to vascular access, Joline is your partner. Joline’s long- and short-term catheters have been specifically designed for use in extracorporeal blood purification procedures such as continuous renal replacement therapy, apheresis, and intermittent hemodialysis. Joline dialysis catheters are high-end, handmade products. They are assembled by hand in a complex manufacturing process.

Joline’s extensive experience in the field of catheter technology enables the company to offer a wide range of dialysis catheters. Premium quality, high value materials together with a unique functional tip design are characteristic of the Joline short-term dialysis catheter and long-term dialysis catheter.

Connecting people and science since 1890, Karger provides scientists, healthcare professionals, patients, and the broader public with reliable and tailored information in Health Sciences. Building upon a publishing portfolio of more than 100 reputable scholarly journals and the award-winning Fast Facts medical info series, Karger excels in medical education and omnichannel HCP engagement in multiple formats, including 3D animations, podcasts, AR/VR environments, and more. Academic institutions and both medical affairs and pharma marketing teams in the corporate space entrust Karger with their most demanding communication challenges. Independent and family-led in the fourth generation by Chairwoman Gabriella Karger, Switzerland-based Karger is present in 15 countries with a team of 200 dedicated professionals worldwide.

KNS MEDICAL is a French company established in Paris since 2016 with a second office in Dubaï. It is a subsidiary of KNS LEASE a well-known French leasing company created in 2001. We are providing renal care centers with dialysis equipments such as dialysis machines, consumables, associated services and financing worldwide. KNS MEDICAL is a one-stop provider for renal care.

Present all over the world, with more than 4000 clients in 12 differents countries, our goal is to allow great access to quality medical care at a lower cost to as many people as possible. We are providing state of art equipments, and tailor-made financing. We also sponsor the opening of dialysis centers. We are working as a strategic partner for a turnkey solution.

Our presence throughout the world is a testimony of our ability to adapt to all challenges, whether operational or budgetary. Whatever your dialysis needs, we have an adequate response.

LiKAMED is a globally leading manufacturer of therapy chairs. Our products combine safety, quality, patient comfort, longevity and cost efficiency with design and more than 40 years of experience. In addition to a wide range of products, we also offer service and technical expertise to cover every needs of our customers all over the world.

As a leading global expert in medical consumables automation, Maider Medical is dedicated to delivering systematic intelligent manufacturing solutions for the healthcare industry. Since pioneering the development of automated production lines for medical consumables, we have evolved into an integrated solutions provider, combining advanced smart equipment, proprietary software platforms, and tailored process development services. Recognized as a domestic leader in medical automation, we empower clients worldwide to achieve operational excellence through innovation.

Our team comprises over 700 professionals from diverse international backgrounds, supported by 200+ R&D specialists driving cutting-edge advancements. Maider Medical has pioneered the development of smart production lines for critical medical devices, including intravenous catheters, hemodialysis filters, prefilled syringes, insulin pen needles, and microcatheters, earning National First-Class Innovation Honor for its groundbreaking technologies.

To date, we have customized 3,000+ systematic solutions for global clients across 50+ countries, fostering partnerships that redefine precision and efficiency and scalability in medical manufacturing. At Maider, we are committed to pioneering the future of intelligent healthcare manufacturing, empowering medical institutions with smart future solutions.

At Maltron International, we specialise in innovative, patented, and non-invasive technologies that support precise Fluid Management and Nutritional Assessment in dialysis care. Maltron BioScan touch i8 provide real-time insights into Fluid distribution and Body Composition helping clinicians accurately assess Dry Weight, detects Fluid Overload monitor Electrolyte Balance and Sarcopenia.

By enabling early detection and personalised treatment, we empower dialysis teams to optimise patient outcomes, reducing complications, and enhance quality of care.

Visit Maltron on stand X2.215 to see how we’re transforming dialysis management through data-driven, patient-focused innovation.

A pioneer in scholarly, open access publishing, MDPI has supported academic communities since 1996. Based in Basel, Switzerland, MDPI has the mission to foster open scientific exchange in all forms, across all disciplines.
Our 469 diverse and open access journals, including 460 peer-reviewed journals and 9 conference journals, are supported by more than 295,000 academic experts who share our mission, values, and commitment to providing high-quality service for our authors. We serve scholars from around the world to ensure the latest research is freely available and all content is distributed under a Creative Commons Attribution License (CC BY).
MDPI’s portfolio comprises at least 237 journals with impact factors, 72% of which are ranked in the top 2 quartiles of their respective fields.

Medcomp develops, manufactures, markets and supports cutting-edge vascular access devices and accessories to meet the clinical needs of the medical industry, particularly in the fields of interventional medicine and dialysis. Our company’s engineering and applications expertise provides superior products whose progressive designs accommodate advances in medicine and whose quality anticipates the requirements of our professional clients and the patients they serve Building on our pioneering Tesio®, Split Cath® and Duo-Flow® products, Medcomp continues to dominate the market in both new and proven dialysis, interventional and accessory devices. Today our contributions to the medical devices field total more than 70 product lines and thousands of distinct products. Currently one of the world’s largest manufacturers of dialysis and centrally terminating venous catheters, Medcomp is, and always has been, on the cutting edge of new vascular access device technologies.

MediBeacon is a medical technology company specializing in the advancement of fluorescent tracer agents and transdermal detection. MediBeacon’s use of proprietary fluorescent tracer agents coupled with transdermal detection technology focuses on providing vital and actionable assessment of organ function. MediBeacon owns over 55 granted U.S. patents and over 215 granted patents worldwide that provide extensive coverage of the MediBeacon® Transdermal GFR System (TGFR), including Lumitrace® injection, the sensor and algorithms, as well as other strategic uses of its proprietary pyrazine platform and sensor technology.

The TGFR is approved by the United States FDA for human use. The TGFR is comprised of the TGFR Sensor, TGFR Monitor, and Lumitrace® (relmapirazin) injection, which together allow assessment of kidney function by measuring the clearance rate of the fluorescent agent as it leaves the body.

The MediBeacon Preclinical MX (not approved for human use) allows calculation and tracking of an animal’s kidney function over time without requiring the animal to be restrained during monitoring. The transdermal GFR methodology (tGFR) is used extensively in preclinical research with over 600 peer-reviewed publications and conference abstracts in which the tGFR technique has been used. MediBeacon is based in St. Louis, Missouri, with additional operations in Mannheim, Germany.

For more information, please visit: www.medibeacon.com

See ifu.medibeacon.com for approved transdermal kidney function products including the Indication for Use and Important Safety Information about the TGFR including Lumitrace® injection.

Medica S.p.A. is a prominent firm specializing in electromedical devices and single-use medical products, boasting more than 50 patents and a dedicated emphasis on innovation and research, backed by a seasoned workforce of 600 staff members with nearly 40 years of industry expertise. Utilizing capillary membrane spinning technology for blood and water purification sets this company apart as the sole Italian entity, showcasing its continuous commitment to technological progress.

For over 75 years, MEDICE has stood for working together to improve people’s health. As a medium-sized family business in its third generation, the MEDICE Health Family pursues the goal of creating a healthier world by considering and promoting the various dimensions of health – mental/physical, social and ecological – in an all-encompassing way.

Quality ‘Made in Germany’: MEDICE develops and produces high-quality medicinal products and medical devices in the prescription (RX) and self-medication (PCC) sectors at its company sites in Iserlohn and Ringelheim and markets them successfully both nationally and internationally. The patient is always at the center of the company’s activities.

The patient is at the center of the MEDICE Health Family’s efforts. In order to further improve patient care, MEDICE uses its pharmacological expertise to develop clinically validated multimodal healthcare solutions that combine pharmaceuticals, digital solutions and nutritional concepts. In this way, the company helps to close gaps in care and supports people at every stage of their illness. This is supported by the establishment of the important pillars Medigital and Medibiom.

The entrepreneurial activities of the MEDICE Health Family are inextricably linked to its social commitment. For decades, MEDICE has not only promoted sport and culture for social health through various (mostly regional) projects, but also the valorization of natural areas and the use of sustainable dispensing articles for ecological health through sustainable4U GmbH, which was founded specifically for this purpose. The values of the MEDICE Health Family – future-focused, value-creating and family-oriented – guide the company here.

Based on its long-standing tradition as a family business, MEDICE – The Health Family aims to play a tangible role in shaping the future of medicine in the coming decade.

MEDIKIT is a leading Japanese manufacturer of medical devices for vascular access such as plastic fistula cannulas and intravenous catheters along with interventional instruments. With more than 50 years of experience, we support hospitals and healthcare services around the world as a strong and reliable technology and service partner. MEDIKIT develops innovative products – like our plastic fistula cannulas with full cover safety mechanism – with a high commitment to quality, and thus intends to contribute to the improvement of treatments and future medical technologies. Our mission is to reduce the burden on patients during the treatment and at the same time improve safety for medical staff. In this way, we want to be of help to the well-being of the societies in which we live.

/

Medtelligence is an independent medical education company specializing in digital education that leverages the creativity of our internal media studio and data analytics team.

We match our combined 295 years of expertise in instructional design with our ability to reach the right learners “wherever they are” together with ReachMD. ReachMD is proven in delivering a high volume of targeted learners through intelligent marketing techniques and personalized strategies. Our combined reach exceeds 5 million healthcare professionals.

Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

As an internationally operating system supplier for medical data processing, MedVision stands for quality and innovation. For over 30 years, we have been developing efficient and economical standard application software for the medical sector.

The safety of our products and the long-lasting satisfaction of our customers are at the core of our quality policy. Our focus is always on meeting our customers’ wishes and providing innovative and economical products and services which help them in their daily tasks and which are safe for patients and users at the same time.In this, our company follows officially recognised standards such as DIN EN ISO 13485.

Our information systems offer a multitude of applications and integrated solutions thus enabling more efficient and economic treatment, care and administration of patients in an unprecedented way. Powerful monitoring, analysing and reporting functionalities optimise the complex processes in medical institutions. This is complemented by interfaces to hospital or laboratory information systems.

With the NEPHRO information system and the accredited QuaNT and SiQuiD benchmarking analysers, MedVision is one of the leading suppliers for nephrological information systems in Germany. OEM versions of our information systems are sold worldwide by our co-operation partners.

Supported by an investment from Medtronic, Inc. and DaVita, Inc.,
Mozarc Medical is a company solely focused on developing breakthrough kidney health technology.
Empowering providers with a holistic, comprehensive portfolio, from access through treatment.
Providing caregivers with unwavering support. And always putting the patient first.

NephroCan is the first and only Canadian company to offer the complete range of products essential for hemodialysis treatment. From dialyzers and bloodlines to machinery (including water treatment systems), all products are manufactured in-house to support reliable care for patients with End Stage Renal Disease (ESRD).

Headquartered in Vancouver, Canada, NephroCan was founded on the principle that every patient deserves to have the best quality therapy built around their specific needs, irrespective of circumstances. Our passion for patient-focused treatment is at the heart of everything we do because we believe that hemodialysis care should be equitable, accessible, and affordable for all.

Full product portfolio includes:

– NephroHDM: hemodialysis machine
– NephroHDX: hemodiafiltration machine
– NephroPRO: water treatment system (Portable Reverse Osmosis Unit)
– NephroCRO: water treatment system (Central Reverse Osmosis Unit)
– NephroChair: patient chair
– NephroNeedle: hemodialysis needles
– NephroLine: hemodialysis bloodlines
– NephroFilter: dialyzers
– NephroBag: sodium bicarbonate bag
– NephroCart: sodium bicarbonate cartridge

Nephrokit is an entity of Gergonne Group whose main objective is to provide to dialysis caregivers solutions that enable the rationalization and standardization of techniques for securing needles and catheters for hemodialysis and reducing bleeding during and after dialysis session.

Nephrolyx delivers precise and rapid kidney function measurement (True GFR), recognized as the gold standard by the 2024 KDIGO CKD guidelines. For the first time, physicians and researchers can directly measure glomerular filtration rate (mGFR) and diagnose or manage kidney disease with unmatched accuracy and speed—eliminating reliance on imprecise estimates. This diagnostic and research technology is particularly valuable in nephrology, donor screening, transplantation, oncology, and intensive care settings.

Nephrolyx’s CE-certified, ready-to-use IVD solution uses quantitative in-vitro serum iohexol determination and delivers measured glomerular filtration rate (mGFR) results within hours, integrating seamlessly into clinical workflows. Nephrolyx is also a reliable partner for research and clinical studies, supporting innovation and precision in renal therapy development.

Nephrolyx’s proprietary technology enhances patient care and healthcare efficiency with its cost-effective True GFR Measurement.

Nephrolyx is available in the US for Research Use Only (RUO).

Nextkidney’s mission is to develop and commercialize the Neokidney home hemodialysis device. Placing the patient and his quality of life at the center of its approach, the company uses innovative technologies to offer a safe, practical and easy-to-use solution as quickly and widely as possible throughout the world.

Nexus Healthcare Education, an independent global provider of medical education, delivers tailored, accessible, and outcome-driven solutions. Our educational programmes address challenges, advance medical knowledge, and enhance clinical practice. We aim to transform global healthcare by driving clinical excellence and innovation through impactful education.

NIKKISO, a pioneer in Renal Replacement Therapies, strives to advance complex medical technologies that optimise patient care in End Stage Renal Disease. Through our commitment to improving clinical efficiency and patient QoL, Nikkiso has built a global reputation for unparalleled quality and innovation. This is mirrored by technical and medical solutions integrated in NIKKISO’s medical and health care devices. Optimising patient care is at the core of our ethos.

DBB-EXA series, our dialysis machines for online hemodialysis (online HD) and online hemodiafiltration (online HDF), provide high-end usability and a wide range of value-oriented solutions and features, achieved by integrating decades of NIKKISO’s expertise in Renal Replacement Therapies.

The DBB-EXA and its integrated automatisms (e.g. automatic priming, treatment start and wash back), and its proven reliability, contribute to the noticeable success of the DBB-EXA in Western Europe countries, underlined by growing market shares and customers satisfaction.

The DBB-EXA ES is today the first launched single pump dialysis machine that performs online priming, online bolus and online wash back in HD treatments.

We, Ningbo D-Tec Medical Supply company, are located in Yinzhou District Ningbo city. With rich experiences on medical device quality system assessment, R&D, risk management, production process, sterilization and quality control, we focus on supplying reliable dialysis products for dialysis clinics and also provide production support for dialysis products manufacturers.

Nowadays our products include: hemodialysis blood tubing set, Arterial venous catheter for hemodialysis (patent product), AV fistula needle; supplies for bi-cart and bi-bag production(such as filing and sealing machine, leakage testing machine, empty bag and empty cartridges etc) and medical plastic components, etc.

Our company has a plant area of nearly 8000 square meters, among which 4000 square meters are class 100,000 cleanrooms that meet GMP requirements. The company’s key members are composed of Ph. Doctors in Biology and Chemistry field who have been engaged in research, operations and management for many years in the blood purification field. The factory is equipped with complete R&D, production facilities, various inspection and testing instruments. Our Factory has established a complete quality management system in accordance with ISO 13485 standard and sterile medical device management practices.

D-TEC always complies with the commercial morality, associated laws and regulations. We do business in good faith and strive to establish sustainable and cooperative relationships with partners to achieve the long-term common development.

Our slogan is “Focus On Quality, Respect For Life”

Nipro is a leading global healthcare company established in Japan in 1954. With over 38 000 employees worldwide, Nipro serves the Medical Device, Pharmaceutical, and Pharma Packaging industries. As a total solution provider of renal care products, medical devices, and pharmapackaging, Nipro supplies life-saving technologies, building long-term, meaningful partnerships with clinics and hospitals around the world. Together with its people, products, and processes, Nipro is committed to improving patient outcomes and quality of life, offering safe and superior products that optimize time, effort, and costs.

Nova Biomedical is a world leader in point of care and critical care in vitro diagnostics. We offer products with a renal function panel, that can be used within or outside the hospital setting.
• NovaMax Pro Creatinine/eGFR® is an important new tool to improve kidney care through kidney function screening and early detection of kidney disease in point-of-care settings outside the hospital. The Nova Max Pro measures blood creatinine and calculates estimated glomerular filtration rate (eGFR), two important indicators of overall kidney function, from a tiny 1.2 microliter capillary fingerstick blood sample in just 30 seconds. Visit us in booth X1.300 for an immediate kidney function screening test.*

• StatSensor® Creatinine measures capillary whole blood creatinine and calculates eGFR to enable a rapid assessment of renal function prior to the administration of nephrotoxic drugs in areas such as Accident & Emergency, Radiology or Oncology.

• Stat Profile Prime Plus® blood gas critical care analyzer with a kidney function panel. Using maintenance-free sensors, the system offers a comprehensive 24-test blood gas menu including tests for iMg, Urea, Creatinine, estimated Plasma Volume (ePV) and CO-Oximetry.

• Allegro®, a compact, capillary blood analyser provides a kidney function panel designed for use in primary care or hospital clinics. The system measures HbA1c, Lipids, Glucose, Creatinine, CRP and PT/INR from capillary whole blood, plus Urine Albumin and Creatinine; with all tests using disposable cartridges and test strips.

*Consult a healthcare professional for questions or concerns about test results.

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease.

Our medicines reached 296 million people worldwide.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

AI in the service of precision medicine. We’re not working miracles, just tools that do.

At Okeiro, we are developing medical AI solutions that are transforming the monitoring of transplant patients and patients suffering from chronic pathologies.

Our predictive algorithms, scientifically validated digital biomarkers, convert complex medical data into information that can be used directly by healthcare teams.

This technology makes it possible to :
– Detect early signals of complications or transplant rejection
– Personalize each treatment for truly proactive management
– Intervene before critical symptoms appear

Our aim is clear: to make a real difference to patients’ lives by equipping healthcare professionals with innovative tools that make a difference every day.

Working closely with healthcare professionals and pharmaceutical companies, we are accelerating the clinical validation of therapeutic innovations to make new treatments more rapidly accessible to the patients who need them!

Otsuka Pharmaceutical is a global healthcare company with the corporate philosophy: ‘Otsuka-people creating new products for better health worldwide.’

Our 35,300 employees channel their passion and commitment into aiming to improve the health of our patients, with a focus in Europe on therapies in mental health, nephrology and immunology, haemato-oncology, infectious diseases and digital therapeutics.

Medical technology can be directed towards an indication or to everyone concerned. We orientate ourselves accordingly. Naturally, the main focus is on the patient, especially where port catheters are concerned. Port systems are intended for long-term use, usually over weeks or even years. A patient must not only live with an illness, but also with the port.

A Leading Provider of Global Independent and Continuing Medical Education
Global physicians and healthcare professionals have been participating in PeerVoice independent medical education for over 18 years to acquire new clinical skills, test their knowledge, and improve their practice of medicine. We carefully design activities to challenge and address the unmet educational needs of the medical community.

All programs are delivered in multiple formats, which can be consumed quickly, at any time, from any place, and on any device using a proven platform which professionals trust.

To find out more, please visit www.peervoice.com

Physidia is a French MedTech company dedicated to advancing renal care through innovative technologies designed for Flexible and Short Home Hemodialysis.
Founded in 2011, Physidia focuses on developing and commercializing safe, efficient, and user-friendly solutions that enable patients with end-stage renal disease (ESRD) to perform frequent hemodialysis at home, in close coordination with their clinical care teams.

The S³ monitor, Physidia’s proprietary home dialysis system, is specifically engineered for frequent home hemodialysis. Its compact footprint, intuitive interface, and integrated data management features make it well-suited for both patients and healthcare providers, while meeting rigourous clinical and safety standards. This approach supports enhanced fluid and metabolic control, better cardiovascular tolerance, and improved patient-reported outcomes compared to conventional thrice-weekly in-center dialysis.

Physidia is committed to expanding access to home-based renal replacement therapy. The company operates in over 18 countries, working in partnership with nephrology teams to support the safe implementation of frequent home hemodialysis programs, from patient information, training to clinical follow-up and remote monitoring.

Our mission is to Make People’s Lives Better by improving Health, Quality of Life and Freedom for Those who are using our innovative solutions.

For further information, visit: www.physidia.com

Through its People, Technology and Service, PTS Diagnostics creates health innovation
that drives action and results. Since 1992, we have helped medical professionals and
patients achieve better health outcomes through our accurate, precise, fast, affordable,
and certified point-of-care medical devices. Healthcare professionals have used our
CardioChek® products to assess cardiovascular disease risks for more than 140 million
patients worldwide through lipid panel screening. And, they’ve used our PTS Connect
biometric information management solutions to turn the data they collect into actionable
reports. Our A1CNow® systems, which provide fast and reliable HbA1c testing, have
helped physicians deliver more effective treatments to patients with diabetes. From our
headquarters in the United States of America, we design, manufacture, and market our
products to more than 140 countries around the globe. For more information, visit
ptsdiagnostics.com

QuidelOrtho Specialty Products Group (SPG) is the option for diagnostics and laboratory products for autoimmune/complement system and bone/renal health research, which are available under the QuidelOrtho MicroVue portfolio. Our products include ELISA, multiplex, antibodies, proteins, and blood based sera. With thousands of citations SPG products have been used successfully in autoimmune kidney research.

Radcliffe CVRM is dedicated to supporting learning among cardiologists, nephrologists, diabetologists, endocrinologists, obesity specialists and primary care physicians for better outcomes in patients with cardiovascular, renal and metabolic conditions.

Our CVRM platform delivers expert-driven, high-quality content across cardiovascular, renal and metabolic health. We emphasise the growing burden of obesity and its associated conditions, including metabolic dysfunction-associated fatty liver disease (MAFLD). Discover insightful articles, dynamic discussions and the latest research summaries from key conferences, keeping you at the forefront of CVRM care.

At RE-INventer consortium, we’re innovating for kidney failure patients. We offer new medical devices: a connected urine analysis solution to monitor the nutrition of pre-dialysis patients, a monitoring system to track the hydration status of dialysis patients, an equipment to secure and detect the disconnection of venous needles, an accessory to collect urinary calculi to analyse and identify kidney stones.

Reliant Glycosciences is a biotechnology company dedicated to developing diagnostic and prognostic tools for patients with IgA nephropathy (IgAN). The company’s objective is to create marketable assays for IgAN-specific biomarkers, making them accessible to both the IgAN research community and pharmaceutical companies interested in developing treatments for this condition.

Reliant offers its own GalD Assay, which measures the level of galactose-deficient IgA1 (Gd-IgA1) in human serum samples. This assay is quantitatively assessed using a lectin-based ELISA test. Reliant aims to make a meaningful impact on the disease and its treatment.

Company Contact: info@reliantglycosciences.com

RİVAMED is a leading manufacturer specializing in medical and industrial water treatment systems. With over 30 years of experience, we have established ourselves as a trusted provider of high-quality water purification solutions for critical applications, particularly in the healthcare sector. Our systems are designed to meet the stringent requirements of hemodialysis clinics, hospitals, laboratories, and pharmaceutical production, ensuring ultra-pure water that complies with international medical standards.

As a Turkey-based company, RİVAMED is the only local manufacturer with MDD 93/42/EEC and MDR 2017/745 EU CE certifications, demonstrating our commitment to quality and patient safety. We deliver world-class water treatment solutions while maintaining competitive pricing and localized support.

Our Global Presence
RİVAMED exports to over 60 countries, providing turnkey installation, after-sales support, and technical services in 34 countries for medical specially hemodialysis solutions. Our ability to offer customized, cost-effective water treatment solutions has made us a preferred partner in Europe, the Middle East, Africa, and Asia.

Our Expertise
We specialize in the design, manufacturing, and installation of:

Hemodialysis Water Treatment Systems (RO systems, endotoxin-free water solutions)
Medical-Grade Reverse Osmosis Systems
Deionization & Ultra-Pure Water Systems
Pharmaceutical Water Purification (WFI Systems)
Industrial Water Treatment for Healthcare & Laboratories
Customized Water Treatment Solutions for Special Medical Applications

✔ Certified Quality: MDR & MDD CE-certified medical water purification systems
✔ Turnkey Solutions: End-to-end service, from system design to after-sales support
✔ Global Reach, Local Expertise: 60+ export countries, 34 with full-service capabilities
✔ Competitive Pricing: High-end systems at cost-effective prices
✔ Strong After-Sales Support: Rapid response times and technical assistance

At RİVAMED, we believe that water is life, and we are dedicated to delivering safe, reliable, and high-performance water purification systems for the medical sector worldwide.

Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
In recognising our endeavour to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the fifteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.

Rontis, a Switzerland based multinational healthcare corporation, was established in 1986 by a group of leading professionals with lengthy experience in the wider healthcare sector and a vision to provide the most innovative & trustworthy solutions in the market, aiming to become an international leader in the global healthcare industry. We have a history in R&D & manufacturing of Medical Devices, Pharmaceuticals, and Dialysis Services.
Medical Devices: we produce disposables for Nephrology, Liquid Administration, as well as products for Interventional Cardiology & Radiology.
Pharmaceuticals: Rontis has a vertically integrated manufacturing system that is supported by the R&D division.
We also provide Original Equipment Manufacturer (OEM) and custom-made solutions.
Website: www.rontis.com

One of the primary concerns in vascular access is the high risk of infections, which can lead to severe complications for patients undergoing treatments like dialysis. SÆPTUM’s HemoPlug™ technology offers a groundbreaking solution by minimizing these risks, thereby enhancing patient safety and outcomes.

Beyond infection control, SÆPTUM focuses on simplifying the patient care pathway. By streamlining processes associated with vascular access, the company’s devices facilitate more efficient and patient-friendly treatment experiences. This ease of use is particularly beneficial for homecare settings, empowering patients to manage their treatments independently and confidently.

The company’s commitment to innovation is underscored by endorsements from leading nephrologists. Professor Bernard Canaud highlights that SÆPTUM’s technology “facilitates extracorporeal treatments, including dialysis, with unparalleled safety and usability,” positioning the company as a transformative force in patient-centered innovation.

SÆPTUM’s multidisciplinary team is driven by a mission to improve vascular access for patients, caregivers, and healthcare systems alike. Through continuous innovation and strategic partnerships, the company is poised to redefine the standards of care in the vascular access field, anticipating and addressing the evolving needs of tomorrow’s healthcare landscape.

In summary, SÆPTUM’s advanced valve system not only reduces infection risks but also simplifies treatment pathways and promotes self-managed homecare. These advancements contribute to enhanced patient quality of life and more efficient healthcare delivery.

Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world’s leading biopharmaceutical company.

Serumwerk is a medium-sized pharmaceutical company with more than 70 years’ tradition in the development and production of medicinal products, medical devices and active pharmaceutical ingredients. Our partners and clients in more than 90 countries have shown trust in our products for decades. Our dialysis portfolio contains sodium chloride solutions, dialyzers, blood tubings and bicarbonate cartridges.

In 1998, Soludia Maghreb laboratory was born from the successful technology transfer from Soludia France to its subsidiary Soludia Maghreb.

Soludia Maghreb Knew how to use Soludia France’s expertise in de hemodialysis field, and orientated its strategic choices towards:

-Proposing quality products, recognized by the European level since 2006, ISO certification 13485 and ISO 9001.
-Insure the development of new formulae to personalize the treatment of the patients.
-Developing new packagings of products to meet better the needs of hemodialysis centers in Morocco.

Soludia maghreb offers you ideally suited solutions to every haemodialysis center namely acid central, 5liter acid bag, cartridge of bicarbonate powder etc.

Conscious of the impacts of competitors and market globalization, which demand a high level of efficiency and latest technologies, we continue to fulfill the challenge.

STADA Specialty Care is a leading provider of innovative medicines across indications including nephrology, CNS and immunology. This portfolio includes the first medicine approved in the EU and the UK for treating the rare kidney disease IgA-Nephropathy (IgAN) as well as an epoetin zeta biosimilar. Other marketed biosimilars cover dermatology, gastroenterology, oncology, osteoporosis and ophthalmology indications, while the group also offers a range of Parkinson’s disease therapies.

Such Specialty medicines account for 21% of STADA’s 2024 group revenues that increased by 9% to EUR 4.1 billion. As Europe’s fourth-largest supplier by value of generic medicines and consumer healthcare products, Germany-based STADA markets its products more than 100 countries worldwide.

SterileCare provides safe and effective solutions that significantly impact preventable complications and associated financial burden of healthcare acquired infections, thereby supporting global action plans on antimicrobial resistance. A primary focus of SterileCare is developing solutions to fight against the threat of serious infections as well as intraluminal care and maintenance of vascular access devices.

SterileCare’s flagship solution is KiteLock™ 4%, a revolutionary product in the fight against complications arising from central venous access devices (CVADs). KiteLock™4%, a catheter lock solution, saves lives by eradicating biofilm, eliminating microorganisms and preventing coagulation in CVADs.

SUBMED is a leading provider of high-quality medical products dedicated to enhancing patient care and supporting healthcare professionals. Founded in 2010 and headquartered in Istanbul/TURKEY, the company has been committed to delivering innovative medical supplies tailored to the needs of the healthcare sector.

At Sobi, we refuse to accept the status quo. This is because we have witnessed first-hand the challenges facing those affected by rare diseases and have used this knowledge to shape our business to find new ways of helping them. As a specialised biopharmaceutical company, we are dedicated to rare diseases. And we see this focus as a strength. By turning our clinical research into ground-breaking treatments, we help make treatments more accessible, opening up more possibilities for people with rare diseases and more opportunities for those caring for them. This has been our approach since day one, but we know we can’t change the world of rare diseases on our own. This requires strong partnerships with patients, partners, and stakeholders across the entire value chain. Together, we define how our business can create solutions that serve the needs of those affected by rare diseases while facilitating sustainable growth.

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline.

In 2000, TauroPharm GmbH was founded as a German company specialising in medical devices with antimicrobial, antibiofilm and antiocclusive efficacy.

Based on its innovative products, we aim to develop more effective ways to prevent catheter-associated complications – ranging from blood clotting to fatal infections. Throughout this process, improving the patient’s quality of life remains our top priority.

Since there is an urgent need for our products, especially in light of the steadily increasing number of antibiotics-resistant pathogens, TauroLock is recommended in interdisciplinary national and international guidelines. All products have been investigated in independent scientific studies with excellent study results.

Products

TauroLock™

TauroLock™-Hep100

TauroLock™-Hep500

TauroLock™-U25.000

NutriLock™

Toray Medical Co., Ltd. is a member company of Toray Group, specializing in healthcare field business.
Toray is a leading manufacturer of synthetic fibers and dedicated to the development of dialysis products under its corporate slogan, “Innovation by Chemistry”. Toray supports high quality and advanced medical care with bio-compatible polymethylmethacrylate dialyzer “FILTRYZER”, high flux polysulfone dialyzer “TORAYSULFONE”, “TORAYLIGHT” and dialysis machine.

Triomed® is a Swedish company dedicated to developing novel innovative therapeutic systems to improve PD. The Steady Concentration PD (SCPD) method offers new possibilities for PD therapy. With the Triomed® system – Carry Life UF – our aim is to keep patients longer on PD by targeting the known limitations of today’s PD treatment options.
The Carry Life UF system uses a low glucose strength PD solution for the initial fill. Throughout the treatment, the system dilutes and mixes small volumes of a concentrated glucose solution with a small portion of the dialysis fluid transferred to the device, before returning it to the patient’s peritoneal cavity.
With Carry Life UF, glucose is added to compensate for the glucose absorption. Thereby a stable dialysate glucose concentration is maintained for the entire duration of the treatment, resulting in a continuous ultrafiltration.
Carry Life UF treatment increased fluid and sodium removal 4 times, compared to a 2.27 % glucose CAPD dwell and with SCPD, glucose can be used more efficiently.

Vantive is a vital organ therapy company on a mission to extend lives and expand possibilities for patients and care teams everywhere. Vantive separated from Baxter in 2025 and is building on a 70-year legacy as a leader in kidney care innovation. Today, patients across more than 100 countries around the world interact with Vantive’s people, solutions and services over 1 million times each day. As we build on our legacy, we are deepening our commitment to elevating the dialysis experience through digital solutions and advanced services, while looking beyond kidney care and investing in transforming vital organ therapies. Greater flexibility and efficiency in therapy administration for care teams, and longer, fuller lives for patients— that is what Vantive aspires to deliver.

Vera Therapeutics is a late-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunologic diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgA nephropathy (IgAN), also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK Virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit www.veratx.com.

Vertex, a global biotechnology company, invests in scientific innovation to create transformative medicines for people with serious diseases. It has approved medicines that treat the underlying causes of cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain and continues to advance its research in these areas. Vertex has a broad and deep clinical pipeline across a range of modalities for other serious diseases like APOL1-mediated kidney disease, IgA nephropathy and autosomal dominant polycystic kidney disease.

Vivisol is one of Europe’s largest Home Care Providers, assisting thousands of patients worldwide.
Everyday Vivisol works in order to support individuals, doctors, and organizations with its products, technologies and services, maintaining a strong focus on innovation and ensuring its solutions are consistently updated to provide patients with the highest quality of service.
Vivisol offers comprehensive home care assistance in the following areas of expertise: Oxygen Therapy, Ventilatory Support, Sleep-related respiratory disturbances, Aerosol Therapy, Artificial Nutrition, Infusion Therapy, At-Home Medical Care, Management of Assistive Devices, Telemedicine, and Chronic Kidney Disease.

Founded in 2004, WEGO Blood Purification Group is dedicated to becoming a global leading provider of blood purification solutions. We are committed to serving patients with kidney disease worldwide by offering high-quality products and professional services across a full spectrum of blood purification therapies, including hemodialysis, peritoneal dialysis, and dialysis care services.

Strong Foundation · Professional Excellence
With over 3,600 employees and 2,000+ medical professionals—WEGO Blood Purification Group has built a service network covering over 6,000 hospitals in China and extending to more than 60 countries and regions worldwide. Our capabilities and reputation continue to grow globally.

Comprehensive Services · Industry Leadership
In China, we operate more than 60 dialysis centers and 4 nephrology specialty hospitals, making us the largest independent dialysis chain in the country. Our dialyzers and bloodline products consistently hold the No.1 market share in China, driven by cutting-edge technology and reliable quality, solidifying our leadership in the field.

Backed by WEGO Group · Globally Oriented
WEGO Blood Purification Group is a subsidiary of WEGO Group, a diversified healthcare conglomerate founded in 1988. With more than 30,000 employees worldwide, WEGO Group owns three publicly listed companies and eight overseas subsidiaries. The Group offers over 1,000 types of medical products and maintains a strong presence in medical devices, pharmaceuticals, and healthcare services, providing robust support for the global development of WEGO Blood Purification Group.

For more information or partnership opportunities, please feel free to contact us.
WEGO Blood Purification Group looks forward to collaborating with partners around the world to advance kidney health and create new value for life.

/

Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited), a leading Indian Pharmaceutical company is a fully integrated, global healthcare provider. With in-depth domain expertise in the field of healthcare, it has strong capabilities across the spectrum of the pharmaceutical value chain. From formulations to active pharmaceutical ingredients and animal healthcare products to wellness products, Zydus has earned a reputation amongst Indian pharmaceutical companies for providing comprehensive and complete healthcare solutions.
Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe.

/

The European Peritoneal Dialysis Conference 2025 (EuroPD 2025) theme is Models of Care.
Under the direction of the Scientific Programme Committee, led by Wim Van Biesen there
will be workshops, plenary lectures, and debates on how we, as a community, can empower
patients to manage their kidney disease at home. Delegates will learn from leading experts in the field of Peritoneal Dialysis (PD), homedialysis, psychology, adult pedagogy, health service research and policy making and those with lived experiences through keynote plenary lectures, concurrent sessions and workshops.

/

The European Society for Paediatric Nephrology (ESPN) was founded in 1967 with the goal of diffusing knowledge and improving the treatment of children with kidney diseases.
ESPN brings together clinical professionals and researchers that operate in the field of Paediatric Nephrology throughout Europe. ESPN has approximately 700 active members.

Our Society has multiple activities including the annual congress, collaborative research projects, teaching courses, workshops, webinars, clinical practice guidelines, a three-year curriculum in Paediatric Nephrology, and a EU-certified board examination in Paediatric Nephrology among others. Within the ESPN, six working groups operate providing focused research and educational opportunities.

The ESPN council includes the President, the Assistant President, a Treasurer (executive councilors), and eight other councilors. Ex officio council members and chair positions include the chair of the ESPN/ERA registry, the President of the annual ESPN congress, chairs of standing and special committees or task forces, chairs of the ESPN working groups, and the chair, vice-chair, and elected representative of the Young Paediatric Nephrology Network (YPNN).

ESPN is the official European partner of the International Pediatric Nephrology Association (IPNA) (https://theipna.org) and is closely associated by mutual agreement with the European Renal Association (ERA) (https://www.era-online.org).

The International Society for Peritoneal Dialysis works to increase the global uptake, promote quality practice, and achieve optimal outcomes of peritoneal dialysis through enhanced advocacy, research, and education, in order to improve the health and well-being of people living with end-stage kidney disease or suffering from acute kidney injury.

As a global organization, the International Society of Renal Nutrition and Metabolism (ISRNM) aims to advance global care in nutrition and metabolism in patients with kidney disease through education, advocacy, research, collaborations, and dissemination of evidence-based knowledge.

ISRNM aspires to optimize the health status and life of patients with kidney disease worldwide through improved care in renal nutrition and metabolism.

The mission of the JSN is to aid in the practice and study of Nephrology. In order to achieve this the JSN conducts a range of activities. These include holding regular meetings as a forum for the diffusion of information, producing regular journals, coordinating clinical research, promoting cooperation with related societies in Japan and internationally, as well as providing recognition to those who have made significant contributions in the field of Nephrology.

PKD International (PKDI) is an independent and global alliance dedicated to improving the lives of 12.5 million individuals affected by Polycystic Kidney Disease (PKD) worldwide.

Our mission is to unite the global PKD community to raise awareness, accelerate research, and amplify the patient voice, transforming patients’ lives worldwide.

Founded in 2011, PKD International is a non-profit, non-governmental association based in Geneva, Switzerland.

Our membership is currently made up of 15 organizations across the world and we are eager to grow this through engagement with existing PKD organizations or by supporting the foundation of others in those countries where one does not yet exist.

/